William Blair analyst Andy Hsieh has reiterated their bullish stance on GPCR stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andy Hsieh has given his Buy rating due to a combination of factors, primarily centered around the promising clinical trial results and market potential of Structure Therapeutics’ aleniglipron. The upcoming Phase IIb ACCESS and ACCESS II trial results are anticipated to showcase significant placebo-adjusted weight loss, which could position aleniglipron favorably against existing treatments like orforglipron. The trials are expected to demonstrate aleniglipron’s efficacy in obesity management, with the potential for higher weight loss in the ACCESS II trial.
Furthermore, Hsieh highlights the strategic advantage of small-molecule GLP-1 receptor agonists in chronic weight management, particularly due to their scalability and supply capabilities compared to peptide-based treatments. The market opportunity is substantial, with a significant portion of the U.S. adult population living with type 2 diabetes, where aleniglipron could play a critical role. The positive data from similar treatments in Phase III trials further supports the potential success of aleniglipron, reinforcing Hsieh’s optimistic outlook on Structure Therapeutics’ market positioning.
According to TipRanks, Hsieh is a 4-star analyst with an average return of 8.2% and a 45.81% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Skye Bioscience, and Terns Pharmaceuticals.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $60.00 price target.